Back to speakers


Associate Professor in Medicine & Gastroenterology


City: Athens

Institution: Laiko General Hospital of Athens
Department of Gastroenterology,
Medical School of National and Kapodistrian University of Athens


Biography of Georgios PAPATHEODORIDIS

George Papatheodoridis is Professor in Medicine and Gastroenterology at Medical School of National and Kapodistrian University of Athens and Director of Academic Gastroenterology Department of Laiko Hospital of Athens, Greece. He was trained in Medicine and completed his PhD thesis at the Medical School of Athens University. He was trained in Gastroenterology at Tzaneion Hospital of Piraeus, Greece and had a 2-year research fellowship in Hepatology at the Royal Free Hospital of London, UK.

He served as member of the Scientific Committee/Governing Board of EASL and is member of EASL and AASLD (fellow). He is president of Hellenic Foundation of Gastroenterology & Nutrition, chair of the Scientific Committee for Viral Hepatitis of Hellenic Center for Prevention of Diseases and chair of the committee for the implementation of the Hellenic National Plan for hepatitis C elimination.

He was president of the Hellenic Association for Study of Liver and general secretary of Hellenic Society of Gastroenterology.

His main research interest has been focused on viral hepatitis. He has (co-)authored >290 papers published in PubMed journals having total IF>1800 and >13500/20000 citations (h-index 58/70) in Scopus/Google Scholar.
He was Associate Editor of Liver International and has served as Editorial Board member of other international journals and as reviewer for all gastroenterology/hepatology journals, many major internal medicine journals (New Engl J Med, Lancet, Ann Intern Med, BMJ etc), ILC/EASL-UEGW abstracts, EU 7th Framework Programme for research and Horizon 2020.
He has given >140 lectures, chaired >45 lectures/round tables and presented >260 abstracts in international meetings.

PHC's participations

Tuesday, March 28th 2023

HCC risk stratification in NUC suppressed HBV patients -

Monday, March 08th 2021

Is Hepatitis Delta underestimated? -

13th PHC – 2020

Monday, January 13th 2020

HEPATITIS DELTA (chairman) -

New epidemiology of hepatitis delta -

12th PHC – 2019

Monday, January 14th 2019

LUNCH WORKSHOPS - 1-New epidemiology and therapeutics in hepatitis delta: Room 252 A -

Tuesday, January 15th 2019

HEPATITIS B - SESSION 2 (chairman)

Monday, January 14th 2019

HBV patient case: effective monitoring and management of patients with hepatitis B

4th PHC – 2011

Tuesday, January 18th 2011

Why do I treat my patient with a nucleos(t)ide analogue? -

5th PHC – 2012

Monday, January 30th 2012

Interactive luncheons - Room 5 -

6th PHC – 2013

Tuesday, January 15th 2013

Why do I treat my patient with a NUC? -

Interactive Luncheons - Room 4

7th PHC – 2014

Tuesday, January 14th 2014

Why do I treat my patient with pegylated IFN? -

11th PHC – 2018

Tuesday, January 16th 2018

HEPATITIS B - SESSION 1 (chairman)

Who and when to treat ? -

CONTROVERSY: To stop or not to stop NUCs ? (chairman)

10th PHC – 2017

Tuesday, January 31st 2017

HEPATITIS B - SESSION 1 (chairman)

LUNCH WORKSHOPS - 10-Long term benefits and side effects of NUC therapy: where are we? (chairman)

8th PHC – 2015

Tuesday, January 13th 2015

How do I treat my HBeAg-positive patients? -

9th PHC – 2016

Monday, January 11th 2016

Lunch Workshops - Room 242A -

Tuesday, January 12th 2016

Do I treat my immunotolerant patients? -